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1.78*; home care, 2.02*; surgery, 1.56*; specialist visits,
1.23; prescription drugs, 1.27. CONCLUSION: Heavy
menstrual ﬂow occurs in 13% of women over age 18, and
is associated with increased use of emergency room visits
and surgery, but not OBGYN or other specialist visits 
or prescription drugs. The results may be interpreted to
mean that many women seek temporary solutions (ER
visits) and may avoid certain types of care, including
drugs.
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The Puregon Pen is a patented medical precision device
to administer follitropin beta solution—recombinant
FSH—for infertility treatment. The Pen can be used for
multiple treatment cycles and requires less RecFSH per
cycle than the traditional syringe and needle. OBJEC-
TIVE: Evaluate the cost consequences of the Puregon 
Pen on the total direct medical costs of an IVF cycle.
METHOD: A Markov model in Excel is used to calcu-
late the total direct medical costs per patient per IVF cycle
using the Pen with follitropin beta solution in a cartridge
versus a traditional syringe and needle with follitropin
alpha powder and solvent for solution. Treatment transi-
tion probabilities and total volume of RecFSH use per IVF
cycle are obtained from published data. Costs are based
on average European prices. RESULTS: The published
data showed an average reduction in RecFSH use with
the Pen of 15.5% (345IU, p < 0.001) compared to the
traditional syringe and needle. Treatment duration was
shorter with the Pen (10.8 vs. 12 days, p = 0.001). No
differences in medical treatment and follow-up or in the
vital pregnancy rate per embryo transfer were identiﬁed.
Using an average European price of €0.55/IU for both
RecFSH products and €100 for the device, the average
total direct medical costs when using the Pen may be
reduced by €90 in the ﬁrst IVF cycle. Every additional IVF
cycle using the Pen may generate an average cost offset
of €190. CONCLUSION: Costs associated with pur-
chasing the Puregon Pen can be offset through shorter
infertility treatment time and less RecFSH use per cycle.
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OBJECTIVES: Traditional hysteroscopic endometrial
ablation techniques are safe and effective though under-
utilized, mainly because of the procedures required spe-
cialized training and had perceived risks. Several new
technologies have been developed; most of which are
blind techniques. A review of the literature was under-
taken to compare the efﬁcacy, safety and acceptability of
second- versus ﬁrst-generation endometrial ablation tech-
niques in DUB. METHODS: Medline, Current Contents,
Cochrane Library, NHS Centre for Reviews and Dissem-
ination and FDA Center for Devices and Radiological
Health were searched from 1981 to March 2002. Bibli-
ographies of relevant articles were screened. Industries
and authors were contacted for information on published
or unpublished data. Experts in the ﬁeld were consulted.
RCTs comparing endometrial ablation techniques in DUB
were eligible for inclusion. Trials of techniques aban-
doned at the time of the review or not published in
English or French were excluded. Outcomes were men-
strual blood loss, satisfaction, quality of life, operative
details, complications, and requirement for further
surgery. RESULTS: Five RCTs were included. They eval-
uated ﬁve new technologies and assessed outcomes one
year after surgery. One trial had long-term follow-up.
Compared to ﬁrst-generation techniques, new technolo-
gies had consistently shorter durations of surgery (11–
27min vs 15–40min), more surgeries performed under
local anesthesia (45–73% vs 8–24%), and fewer intra-
operative complications (0–1,1% vs 2,4–5,8%). At 12
months, clinical outcomes results were similar between
the 2 generations. Results remained similar, with little dif-
ference at three years compared with results at one year.
CONCLUSION: There was no clear difference in clinical
outcomes between second- and ﬁrst-generation tech-
niques. Advantages include ease of use, short operative
time, choice of anesthesia and reduced risk of intraoper-
ative complications. Risk of inadvertent perforation and
subsequent injury to bowel exists. Long-term safety and
efﬁcacy, cost-effectiveness and safety in use by the general
gynecologist remain to be studied.
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OBJECTIVE: There is some evidence that aging deterio-
rates the Health Related Quality of Life (HRQOL) in
physical area, although mental area remains stable, even
suffering chronic diseases, because of adaptation mecha-
